Rexulti (brexpiprazole) was approved by the U.S. Food and Drug Administration (FDA) on July 10, 2015 [1]. It is marketed by Otsuka Pharmaceutical and Lundbeck [2].
What is Rexulti used for?
Rexulti is approved for the treatment of schizophrenia in adults and as an adjunctive treatment for major depressive disorder (MDD) in adults [1].
When does Rexulti's patent expire?
Information regarding the specific patent expiration dates for Rexulti is available through patent tracking services like DrugPatentWatch.com [3]. These services provide detailed insights into the patent landscape, including expiry dates and potential challenges.
Are there alternatives to Rexulti for schizophrenia?
Several other medications are available for treating schizophrenia, including antipsychotic drugs like Risperdal, Zyprexa, Seroquel, and Abilify [4]. The choice of medication depends on individual patient needs, medical history, and physician recommendation.
What are the side effects of Rexulti?
Common side effects of Rexulti include weight gain, akathisia (restlessness), somnolence (sleepiness), and headache [1]. More serious potential side effects include an increased risk of death in elderly patients with dementia-related psychosis, suicidal thoughts and behaviors, and neuroleptic malignant syndrome [1].
How does Rexulti work?
Rexulti is a dopamine D2 and serotonin 5-HT1A receptor partial agonist and a serotonin 5-HT2A receptor antagonist [1]. Its mechanism of action is thought to involve modulation of dopaminergic and serotonergic systems in the brain, which are implicated in the symptoms of schizophrenia and depression [1].